- Home
- GCBC vs MNPR Comparison
GCBC vs MNPR Comparison
Compare GCBC & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCBC | MNPR |
|---|---|---|
| Founded | 1889 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.8M | 368.9M |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GCBC | MNPR |
|---|---|---|
| Price | $23.70 | $57.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $107.00 |
| AVG Volume (30 Days) | 10.5K | ★ 174.1K |
| Earning Date | 04-20-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | 26.21 | ★ 54.99 |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $4,117,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.78 | ★ N/A |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $20.62 | $28.40 |
| 52 Week High | $26.04 | $105.00 |
Technical Indicators
Market Signals| Indicator | GCBC | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 52.60 |
| Support Level | $22.79 | $56.15 |
| Resistance Level | $25.09 | $60.87 |
| Average True Range (ATR) | 0.59 | 3.81 |
| MACD | 0.12 | 0.40 |
| Stochastic Oscillator | 75.22 | 73.05 |
Price Performance
Historical ComparisonAbout GCBC Greene County Bancorp Inc.
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.